Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks.

Julian Olalla SierraJavier Pérez-StachowskiBegoña TortajadaAlfonso Del ArcoEfrén MárquezJavier De la TorreMiriam NietoJosé María García de LomasJosé Luis PradaJavier García-Alegría

Published in: BMC pharmacology & toxicology (2018)

The change from a regimen of abacavir + lamivudine + dolutegravir seems to be safe and effective at 24 weeks.

Keyphrases

hiv infected patients
antiretroviral therapy
gestational age
electronic health record
big data
artificial intelligence
deep learning